• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Entrada Therapeutics Inc. (Amendment)

    2/14/23 4:25:49 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRDA alert in real time by email
    SC 13G/A 1 tm236041d13_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

    ENTRADA THERAPEUTICS, INC.

     

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

     

    (Title of Class of Securities)

     

     

    29384C108

     

    (CUSIP Number)

     

     

    December 31, 2022

     

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨    Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 29384C108

    1

    Name of Reporting Person

     

    Redmile Group, LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    1,854,108 (1)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    1,854,108 (1)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,854,108 (1)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    5.9% (2)

    12

    Type of Reporting Person (See Instructions)

     

    IA, OO

     

     

    (1) Redmile Group, LLC’s beneficial ownership of the Issuer’s Common Stock, par value $0.0001 per share (“Common Stock”) is comprised of 1,854,108 shares of Common Stock owned by certain private investment vehicles managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    (2) Percentage based on 31,406,165 shares of Common Stock outstanding as of October 31, 2022, as reported by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2022 filed with the Securities and Exchange Commission on November 7, 2022 (the “Form 10-Q”).

     

     

     

     

    CUSIP No. 29384C108

    1

    Name of Reporting Person

     

    Jeremy C. Green

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United Kingdom

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    1,854,108 (3)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    1,854,108 (3)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,854,108 (3)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    5.9% (4)

    12

    Type of Reporting Person (See Instructions)

     

    IN, HC

     

     

    (3) Jeremy C. Green’s beneficial ownership of Common Stock is comprised of 1,854,108 shares of Common Stock owned by certain private investment vehicles managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    (4) Percentage based on 31,406,165 shares of Common Stock outstanding as of October 31, 2022, as reported by the Issuer in the Form 10-Q.

     

     

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Entrada Therapeutics, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    6 Tide Street
    Boston, Massachusetts 02210

     

    Item 2.

     

    (a)Names of Persons Filing

     

    Redmile Group, LLC
    Jeremy C. Green

     

    (b)Address of Principal Business office or, if None, Residence

     

    Redmile Group, LLC
    One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129

     

    Jeremy C. Green
    c/o Redmile Group, LLC (NY Office)
    45 W. 27th Street, Floor 11
    New York, NY 10001

     

    (c)Citizenship

     

    Redmile Group, LLC: Delaware
    Jeremy C. Green: United Kingdom

     

    (d)Title of Class of Securities

     

    Common Stock, par value $0.0001 per share

     

    (e)CUSIP Number

     

    29384C108

     

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a)  ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
           
      (b)  ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c)  ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

     

     

     

      (d)  ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
           
      (e)  x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f)  ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g)  x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h)  ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i)  ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)  ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k)  ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    Redmile Group, LLC – 1,854,108 *
    Jeremy C. Green – 1,854,108 *

      

    (b)Percent of class:

     

    Redmile Group, LLC – 5.9%**
    Jeremy C. Green – 5.9%**

     

     

    (c)Number of shares as to which Redmile Group, LLC has:

     

    (i)Sole power to vote or to direct the vote:

     

     0

     

    (ii)Shared power to vote or to direct the vote:

     

     1,854,108 *

     

    (iii)Sole power to dispose or to direct the disposition of:

     

     0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    1,854,108 *

     

    Number of shares as to which Jeremy C. Green has:

     

    (i)Sole power to vote or to direct the vote:

     

     0

     

     

     

     

    (ii)Shared power to vote or to direct the vote:

     

    1,854,108*

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    1,854,108*

     

    *Redmile Group, LLC’s and Jeremy C. Green’s beneficial ownership of the Issuer’s Common Stock is comprised of 1,854,108 shares of Common Stock owned by certain private investment vehicles managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    **Percentage based on 31,406,165 shares of Common Stock outstanding as of October 31, 2022, as reported by the Issuer in the Form 10-Q.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    See the response to Item 4.

     

    Item 8.Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9.Notice of Dissolution of Group.

     

    N/A

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2023

      

     

    Redmile Group, LLC

         
      By: /s/ Jeremy C. Green  
       

    Name: Jeremy C. Green

    Title: Managing Member

         
        /s/ Jeremy C. Green
     

     

    Jeremy C. Green

     

     

     

    Get the next $TRDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRDA

    DatePrice TargetRatingAnalyst
    12/6/2024$29.00Buy
    ROTH MKM
    1/5/2024$22.00Outperform
    Oppenheimer
    4/3/2023$25.00Buy
    H.C. Wainwright
    11/24/2021Outperform
    Evercore ISI Group
    11/23/2021Outperform
    Cowen & Co.
    11/23/2021$29.00Neutral
    Goldman Sachs
    More analyst ratings

    $TRDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Entrada Therapeutics with a new price target

      ROTH MKM initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $29.00

      12/6/24 8:19:11 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Entrada Therapeutics with a new price target

      Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $22.00

      1/5/24 8:45:46 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Entrada Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $25.00

      4/3/23 7:39:53 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Entrada Therapeutics Inc.

      DEFA14A - Entrada Therapeutics, Inc. (0001689375) (Filer)

      6/3/25 7:45:52 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entrada Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)

      6/3/25 7:05:10 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Entrada Therapeutics Inc.

      SCHEDULE 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

      5/14/25 12:28:53 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

      6/3/25 7:00:00 AM ET
      $BIIB
      $TRDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

      āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,

      9/17/24 8:30:00 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

      BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. "Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Wit

      8/10/23 7:00:00 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

      BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

      6/3/25 7:00:00 AM ET
      $BIIB
      $TRDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units ("RSUs") to six newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the "Inducement Plan"), effective as of June 1, 2025. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest quart

      6/2/25 4:30:00 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

      – Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial Regulation (EU-CTR) to initiate ELEVATE-45-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-45 in patients living with Duchenne muscular dystrophy (DMD) who are amenable to exon 45 skipping. "ELEVATE-45-201 is the most advanced clinical

      5/28/25 7:00:00 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kim Peter S bought $364,672 worth of shares (25,000 units at $14.59), increasing direct ownership by 37% to 92,412 units (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      5/16/24 4:33:48 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kim Peter S bought $63,306 worth of shares (4,476 units at $14.14), increasing direct ownership by 7% to 67,412 units (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      5/10/24 4:35:37 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kim Peter S bought $35,290 worth of shares (2,600 units at $13.57), increasing direct ownership by 4% to 62,936 units (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      4/10/24 4:35:18 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Radhakrishnan Maha

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      6/3/25 8:13:04 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Radhakrishnan Maha

      3 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      6/3/25 8:11:16 AM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Wentworth Kory James exercised 11,134 shares at a strike of $2.10, increasing direct ownership by 10% to 120,670 units (SEC Form 4)

      4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

      4/4/25 4:34:29 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Entrada Therapeutics Inc.

      SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

      11/14/24 1:22:40 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Entrada Therapeutics Inc.

      SC 13D/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

      6/26/24 4:54:17 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Entrada Therapeutics Inc. (Amendment)

      SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

      2/14/24 4:26:22 PM ET
      $TRDA
      Biotechnology: Pharmaceutical Preparations
      Health Care